Cargando…

METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation

The aim of the present study was to clarify the mechanism of how METTL3 regulated pancreatic ductal adenocarcinoma (PDAC) progression by m6A modification of its downstream target mRNA and signaling pathway. Immunoblotting and qRT-PCR assays was employed to determine the expression levels of METTL3....

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chengjie, Li, Ting, Wang, Yan, Lai, Shihui, Huang, Yue, Guo, Zhenyun, Zhang, Xiang, Weng, Shangeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050319/
https://www.ncbi.nlm.nih.gov/pubmed/36977668
http://dx.doi.org/10.1038/s41419-023-05715-1
_version_ 1785014623810879488
author Lin, Chengjie
Li, Ting
Wang, Yan
Lai, Shihui
Huang, Yue
Guo, Zhenyun
Zhang, Xiang
Weng, Shangeng
author_facet Lin, Chengjie
Li, Ting
Wang, Yan
Lai, Shihui
Huang, Yue
Guo, Zhenyun
Zhang, Xiang
Weng, Shangeng
author_sort Lin, Chengjie
collection PubMed
description The aim of the present study was to clarify the mechanism of how METTL3 regulated pancreatic ductal adenocarcinoma (PDAC) progression by m6A modification of its downstream target mRNA and signaling pathway. Immunoblotting and qRT-PCR assays was employed to determine the expression levels of METTL3. In situ fluorescence hybridization was conducted to localize the cellular distribution of METTL3 and DEAD-box helicase 23 (DDX23). CCK8, colony formation, EDU incorporation, TUNEL, wound healing and Transwell assays were carried out accordingly to study the viability, proliferation, apoptosis, and mobility of cells under different treatments in vitro. Xenograft and animal lung metastasis experiments were also conducted to study the functional role of METTL3 or DDX23 on tumor growth and lung metastasis in vivo. MeRIP-qPCR and bioinformatical analyses were used to obtain the potential direct targets of METTL3. It was shown that m6A methyltransferase METTL3 was upregulated in PDAC tissues with gemcitabine resistance, and its knockdown sensitized pancreatic cancer cells to chemotherapy. Furthermore, silencing METTL3 remarkably reduced pancreatic cancer cell proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, validation experiments confirmed that DDX23 mRNA was a direct target of METTL3 in YTHDF1-dependent manner. Additionally, DDX23 silence resulted in the suppression of pancreatic cancer cell malignancy and PIAK/Akt signaling inactivation. Strikingly, rescuse experiments demonstrated the inhibitive effects of METTL3 silence on cell phenotypes and gemcitabine resistance were partially reversed by forcibly expressed DDX23. In summary, METTL3 promotes PDAC progression and gemcitabine resistance by modifying DDX23 mRNA m6A methylation and enhancing PI3K/Akt signaling activation. Our findings establish a potential tumor promotive and chemo-resistant role for METTL3/DDX23 axis in PDAC.
format Online
Article
Text
id pubmed-10050319
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100503192023-03-30 METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation Lin, Chengjie Li, Ting Wang, Yan Lai, Shihui Huang, Yue Guo, Zhenyun Zhang, Xiang Weng, Shangeng Cell Death Dis Article The aim of the present study was to clarify the mechanism of how METTL3 regulated pancreatic ductal adenocarcinoma (PDAC) progression by m6A modification of its downstream target mRNA and signaling pathway. Immunoblotting and qRT-PCR assays was employed to determine the expression levels of METTL3. In situ fluorescence hybridization was conducted to localize the cellular distribution of METTL3 and DEAD-box helicase 23 (DDX23). CCK8, colony formation, EDU incorporation, TUNEL, wound healing and Transwell assays were carried out accordingly to study the viability, proliferation, apoptosis, and mobility of cells under different treatments in vitro. Xenograft and animal lung metastasis experiments were also conducted to study the functional role of METTL3 or DDX23 on tumor growth and lung metastasis in vivo. MeRIP-qPCR and bioinformatical analyses were used to obtain the potential direct targets of METTL3. It was shown that m6A methyltransferase METTL3 was upregulated in PDAC tissues with gemcitabine resistance, and its knockdown sensitized pancreatic cancer cells to chemotherapy. Furthermore, silencing METTL3 remarkably reduced pancreatic cancer cell proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, validation experiments confirmed that DDX23 mRNA was a direct target of METTL3 in YTHDF1-dependent manner. Additionally, DDX23 silence resulted in the suppression of pancreatic cancer cell malignancy and PIAK/Akt signaling inactivation. Strikingly, rescuse experiments demonstrated the inhibitive effects of METTL3 silence on cell phenotypes and gemcitabine resistance were partially reversed by forcibly expressed DDX23. In summary, METTL3 promotes PDAC progression and gemcitabine resistance by modifying DDX23 mRNA m6A methylation and enhancing PI3K/Akt signaling activation. Our findings establish a potential tumor promotive and chemo-resistant role for METTL3/DDX23 axis in PDAC. Nature Publishing Group UK 2023-03-28 /pmc/articles/PMC10050319/ /pubmed/36977668 http://dx.doi.org/10.1038/s41419-023-05715-1 Text en © The Author(s) 2023, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Lin, Chengjie
Li, Ting
Wang, Yan
Lai, Shihui
Huang, Yue
Guo, Zhenyun
Zhang, Xiang
Weng, Shangeng
METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
title METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
title_full METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
title_fullStr METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
title_full_unstemmed METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
title_short METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
title_sort mettl3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying ddx23 mrna n6 adenosine methylation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050319/
https://www.ncbi.nlm.nih.gov/pubmed/36977668
http://dx.doi.org/10.1038/s41419-023-05715-1
work_keys_str_mv AT linchengjie mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation
AT liting mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation
AT wangyan mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation
AT laishihui mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation
AT huangyue mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation
AT guozhenyun mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation
AT zhangxiang mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation
AT wengshangeng mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation